OR WAIT null SECS
January 10, 2024
MHRA has granted a Clinical Trial Authorization to PharmaKure for its oral combined drug for the treatment of mild cognitive impairment.
Nanoform has completed the First Subject First Visit in a trial evaluating the relative bioavailability of its nanotechnology-enhanced enzalutamide.
January 03, 2024
European bio/pharma companies have no choice but to invest and adapt to the evolving industry needs.
Novel molecular glues are transforming targeted protein degradation.
UK scientists are once again able to participate in the Horizon European research programme thanks to a deal struck in 2023.
January 02, 2024
The EHDS aims to increase access to health data, but how will it impact pharma?
Clarivate has released its 2024 Drugs to Watch report, highlighting 13 therapies with great potential.
December 27, 2023
The midterm report of the European Medicines Agencies Network Strategy finds that the network has strengthened and is on track to achieve its objectives.
December 21, 2023
The agencies published a joint guidance document regarding quality development for breakthrough therapies and PRIME programs.
December 20, 2023
Under a collaboration, Daiichi Sankyo and Depixus will use Depixus’ MAGNA technology to accelerate drug discovery efforts of RNA-targeted therapeutics.